PainReform Ltd. (PRFX)
USD 2.36
(2.61%)
USD 2.36
(2.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.56 Million USD | -9.9% |
| 2022 | -8.85 Million USD | -20.75% |
| 2021 | -7.2 Million USD | -314.66% |
| 2020 | -1.67 Million USD | -135.96% |
| 2019 | -688 Thousand USD | -47.11% |
| 2018 | - USD | 58.6% |
| 2017 | -1.21 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.56 Million USD | -56.3% |
| 2024 Q2 | -7.34 Million USD | -32.01% |
| 2023 Q2 | -2.24 Million USD | 7.24% |
| 2023 Q1 | -2.41 Million USD | 23.8% |
| 2023 FY | - USD | -9.9% |
| 2023 Q4 | -3.55 Million USD | -18.8% |
| 2023 Q3 | -2.99 Million USD | -33.59% |
| 2022 Q3 | -2.01 Million USD | -9.11% |
| 2022 Q2 | -1.84 Million USD | -10.48% |
| 2022 Q1 | -1.67 Million USD | 4.13% |
| 2022 FY | - USD | -20.75% |
| 2022 Q4 | -3.17 Million USD | -57.58% |
| 2021 FY | - USD | -314.66% |
| 2021 Q2 | -1.7 Million USD | 16.67% |
| 2021 Q3 | -1.76 Million USD | -4.06% |
| 2021 Q4 | -1.74 Million USD | 1.53% |
| 2021 Q1 | -2.04 Million USD | -169.48% |
| 2020 FY | - USD | -135.96% |
| 2020 Q4 | -757 Thousand USD | -7.99% |
| 2020 Q1 | -132 Thousand USD | 41.01% |
| 2020 Q2 | -149 Thousand USD | -12.88% |
| 2020 Q3 | -701 Thousand USD | -370.47% |
| 2019 Q3 | -493 Thousand USD | -34.33% |
| 2019 FY | - USD | -47.11% |
| 2019 Q1 | -367 Thousand USD | -3.97% |
| 2019 Q2 | -367 Thousand USD | 0.0% |
| 2019 Q4 | -223.75 Thousand USD | 54.61% |
| 2018 Q1 | -334 Thousand USD | 0.0% |
| 2018 Q2 | -334 Thousand USD | 0.0% |
| 2018 Q3 | -353 Thousand USD | -5.69% |
| 2018 FY | - USD | 58.6% |
| 2018 Q4 | -353 Thousand USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 93.625% |
| Theratechnologies Inc. | -10.31 Million USD | 7.212% |
| Safety Shot Inc | -12.18 Million USD | 21.47% |
| Cosmos Health Inc. | -17.06 Million USD | 43.916% |
| Cronos Group Inc. | -72.14 Million USD | 86.737% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 98.965% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 73.48% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 126.558% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -197.63% |
| ProPhase Labs, Inc. | -14.82 Million USD | 35.462% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -111.47% |
| Dynavax Technologies Corporation | 9.66 Million USD | 198.996% |
| Radius Health, Inc. | 38.31 Million USD | 124.978% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -307.017% |
| Alvotech | -484.86 Million USD | 98.026% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -150.208% |
| Alpha Teknova, Inc. | -25.53 Million USD | 62.532% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 93.976% |
| SCYNEXIS, Inc. | 73.47 Million USD | 113.023% |
| Harrow Health, Inc. | 9.72 Million USD | 198.416% |
| Biofrontera Inc. | -18.45 Million USD | 48.144% |
| DURECT Corporation | -24.68 Million USD | 61.234% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 109.738% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 108.753% |
| OptiNose, Inc. | -15.55 Million USD | 38.475% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 136.431% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 909.56% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -1246.135% |
| SIGA Technologies, Inc. | 84.15 Million USD | 111.37% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 1278.448% |
| Shineco, Inc. | -26.55 Million USD | 63.964% |
| Phibro Animal Health Corporation | 84.6 Million USD | 111.31% |
| Procaps Group S.A. | 104.02 Million USD | 109.199% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -13.903% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -164.51% |
| Viatris Inc. | 3.51 Billion USD | 100.272% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -150.208% |
| Rockwell Medical, Inc. | -4.69 Million USD | -103.856% |
| Incannex Healthcare Limited | -18.5 Million USD | 48.287% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -845.553% |
| Tilray Brands, Inc. | -72.84 Million USD | 86.864% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 103.104% |
| PetIQ, Inc. | 81.48 Million USD | 111.743% |
| Silver Spike Investment Corp. | 7.34 Million USD | 230.366% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 102.3% |
| Journey Medical Corporation | 1.92 Million USD | 598.126% |
| Alimera Sciences, Inc. | 7.27 Million USD | 231.515% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -127.191% |
| Assertio Holdings, Inc. | -222.44 Million USD | 95.698% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -139.786% |
| Embecta Corp. | 245.4 Million USD | 103.899% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 52.229% |
| Procaps Group, S.A. | 104.02 Million USD | 109.199% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 93.583% |
| Hempacco Co., Inc. | -12.77 Million USD | 25.086% |
| Talphera, Inc. | -9.84 Million USD | 2.774% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 105.874% |
| Alvotech | -484.86 Million USD | 98.026% |
| Lantheus Holdings, Inc. | 491 Million USD | 101.949% |
| Kamada Ltd. | 21.53 Million USD | 144.437% |
| Indivior PLC | 66 Million USD | 114.498% |
| Currenc Group, Inc. | -1.9 Million USD | -403.479% |
| Evoke Pharma, Inc. | -7.29 Million USD | -31.221% |
| Flora Growth Corp. | -45.87 Million USD | 79.139% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 52.229% |
| Evolus, Inc. | -41.81 Million USD | 77.113% |
| HUTCHMED (China) Limited | 25.52 Million USD | 137.484% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 103.963% |
| Akanda Corp. | -27.73 Million USD | 65.499% |